Oral vaccines against cholera

Clinical Infectious Diseases

Volumn 52, Issue 11, 2011, Pages 1343-1349

  Plotkin, Stanley ^a   Shin, Sunheang ^a   Desai, Sachin N ^a   Sah, Binod K ^a   Clemens, John D ^a  

^a International Vaccine Institute   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; MUTACOL; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL VIRULENCE; CHOLERA; IMMUNE RESPONSE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SANITATION; VIBRIO CHOLERAE;

ADMINISTRATION, ORAL; CHOLERA; CHOLERA VACCINES; COMMUNICABLE DISEASE CONTROL; DEVELOPING COUNTRIES; HUMANS; PANDEMICS;

EID: 79957448582     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir141     Document Type: Article

References (53)

1. World Health Organisation. WHO report on global surveillance of epidemic-prone infectious diseases. 2000; 39-54. Available online at http://www.who.int/csr/resources/publications/surveillance/WHO-Report- Infectious-Diseases.pdf. Accessed 4 March 2011.
2. Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet 2004; 363:223-33.
3. Siddique AK, Nair GB, Alam M, et al. El Tor cholera with severe disease: A new threat to Asia and beyond. Epidemiol Infect 2010; 138:347-52.
4. World Health Organisation. Cholera, 2009. Wkly Epidemiol Rec 2010; 85:293-307.
5. Zuckerman JN, Rombo L, Fisch A. The true burden and risk of cholera: Implications for prevention and control. Lancet Infect Dis 2007; 7:521-30. (Pubitemid 47079151)
6. Deen JL, von Seidlein L, Sur D, et al. The high burden of cholera in children: Comparison of incidence from endemic areas in Asia and Africa. PLoS Negl Trop Dis 2008; 2:e173.
7. Siddique AK, Salam A, Islam MS, et al. Why treatment centres failed to prevent cholera deaths among Rwandan refugees in Goma, Zaire. Lancet 1995; 345:359-61.
8. Cholera in Central Africa: Global Alert and Response (GAR). http://www.who.int/csr/don/2010-10-08/en/index.html. Accessed 8 October 2010.
9. Health Cluster Bulletin #15, Pan American Health Organization. http://new.paho.org/hai/index.php?lang5en. Accessed 25 January 2011.
10. Huq A, Sack RB, Nizam A, et al. Critical factors influencing the occurrence of Vibrio cholerae in the environment of Bangladesh. Appl Environ Microbiol 2005; 71:4645-54. (Pubitemid 41129521)
11. Sanchez J, Holmgren J. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr Opin Immunol 2005; 17:388-98. (Pubitemid 40848541)
12. Cash RA, Music SI, Libonati JP, Craig JP, Pierce NF, Hornick RB. Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J Infect Dis 1974; 130:325-33.
13. Albert MJ, Alam K, Rahman AS, Huda S, Sack RB. Lack of crossprotection against diarrhea due to Vibrio cholerae O1 after oral immunization of rabbits with V. cholerae O139 Bengal. J Infect Dis 1994; 169:709-10. (Pubitemid 24063035)
14. Mosley WH, Ahmad S, Benenson AS, Ahmed A. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull World Health Organ 1968; 38:777-85.
15. Clemens JD, Sack DA, Rao MR, et al. Evidence that inactivated oral cholera vaccines both prevent and mitigate Vibrio cholerae O1 infections in a cholera-endemic area. J Infect Dis 1992; 166:1029-34.
16. Mosley WH, Aziz KM, Mizanur Rahman AS, Alauddin Chowdhury AK, Ahmed A, Fahimuddin M. Report of the 1966-67 cholera vaccine trial in rural East Pakistan. Bull World Health Organ 1972; 47:229-38.
17. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11(Suppl 4):S45-53. (Pubitemid 40562303)
18. Background paper on the integration of oral cholera vaccines into global cholera programmes. World Health Organization Strategic Advisory Group of Experts (SAGE) on Immunization, 2009; 1-74. Available online at: http://www.who.int/immunization/sage/1-Background-Paper-Cholera-Vaccines- FINALdraft-13-oct-v2.pdf.
19. Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh: Results from three-year follow-up. Lancet 1990; 335:270-3. (Pubitemid 20047723)
20. Clemens JD, Sack DA, Harris JR, et al. Cross-protection by B subunitwhole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: Results of a large-scale field trial. J Infect Dis 1988; 158:372-7.
21. Sanchez JL, Vasquez B, Begue RE, et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 1994; 344:1273-6. (Pubitemid 24334686)
22. Taylor DN, Cardenas V, Sanchez JL, et al. Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru. J Infect Dis 2000; 181:1667-73. (Pubitemid 30387759)
23. Clemens JD, Sack DA, Ivanoff B. Misleading negative findings in a field trial of killed, oral cholera vaccine in Peru. J Infect Dis 2001; 183:1306-9. (Pubitemid 32281577)
24. Lucas MES, Deen JL, von Seidlein L, et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. New Engl J Med 2005; 352:757-67. (Pubitemid 40271170)
25. Trach DD, Clemens JD, Ke NT, et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 1997; 349:231-5. (Pubitemid 27050988)
26. Thiem VD, Deen JL, von Seidlein L, et al. Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine 2006; 24:4297-303.
27. World Health Organization. WHO expert committee on Biological standardization, 52nd report. Geneva, Switzerland: WHO, 2004.
28. Anh DD, Canh DG, Lopez AL, et al. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 2007; 25:1149-55. (Pubitemid 44963512)
29. Mahalanabis D, Lopez AL, Sur D, et al. A randomized, placebocontrolled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS One 2008; 3:e2323.
30. Sur D, Lopez AL, Kanungo S, et al. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: An interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:1694-702.
31. Holmgren J, Kaper J. Oral cholera vaccines, 4th ed. New York, New York: Marcel Deker, 2009.
32. Tacket CO, Losonsky G, Nataro JP, et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis 1992; 166:837-41.
33. Richie EE, Punjabi NH, Sidharta YY, et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000; 18:2399-410. (Pubitemid 30156811)
34. Calain P, Chaine J-P, Johnson E, et al. Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine 2004; 22:2444-51. (Pubitemid 38757343)
35. Qadri F, Chowdhury MI, Faruque SM, et al. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 2007; 25:231-8. (Pubitemid 44856084)
36. Garcia L, Jidy MD, Garcia H, et al. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect Immun 2005; 73:3018-24. (Pubitemid 40570371)
37. Liang W, Wang S, Yu F, et al. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108. Infect Immun 2003; 71:5498-504. (Pubitemid 37205600)
38. Yan M, Liu G, Diao B, et al. A Vibrio cholerae serogroup O1 vaccine candidate against CTX ET Phi infection. Vaccine 2007; 25:4046-55. (Pubitemid 46628986)
39. Mahalanabis D, Ramamurthy T, Nair GB, et al. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response. Vaccine 2009; 27:4850-6.
40. Coster TS, Killeen KP, Waldor MK, et al. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet 1995; 345:949-52.
41. Tacket CO, Losonsky G, Nataro JP, et al. Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: Safety and efficacy against experimental challenge. J Infect Dis 1995; 172:883-6.
42. Naficy A, Rao MR, Paquet C, Antona D, Sorkin A, Clemens JD. Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings: A cost-effectiveness analysis. JAMA 1998; 279:521-5. (Pubitemid 28113430)
43. Clemens J, Holmgren J. Urgent need of cholera vaccines in public health-control programs. Future Microbiol 2009; 4:381-5.
44. AliM, EmchM, von Seidlein L, et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: A reanalysis. Lancet 2005; 366:44-9. (Pubitemid 40956529)
45. Longini IM Jr., Nizam A, Ali M, Yunus M, Shenvi N, Clemens JD. Controlling endemic cholera with oral vaccines. PLoS Med 2007; 4:e336.
46. Vu DT, Hossain MM, Nguyen DS, et al. Coverage and costs of mass immunization of an oral cholera vaccine in Vietnam. J Health Popul Nutr 2003; 21:304-8. (Pubitemid 38332083)
47. Cavailler P, Lucas M, Perroud V, et al. Feasibility of a mass vaccination campaign using a two-dose oral cholera vaccine in an urban cholera-endemic setting in Mozambique. Vaccine 2006; 24: 4890-5. (Pubitemid 43792486)
48. Dorlencourt F, Legros D, Paquet C, Neira M, Ivanoff B, Le Saout E. Effectiveness of mass vaccination with WC/rBS cholera vaccine during an epidemic in Adjumani district, Uganda. Bull World Health Organ 1999; 77:949-50.
49. Chaignat C-L, Monti V, Soepardi J, et al. Cholera in disasters: Do vaccines prompt new hopes? Expert Rev Vaccines 2008; 7:431-5. (Pubitemid 351656814)
50. Murray J, McFarland DA, Waldman RJ. Cost-effectiveness of oral cholera vaccine in a stable refugee population at risk for epidemic cholera and in a population with endemic cholera. Bull World Health Organ 1998; 76:343-52. (Pubitemid 28469267)
51. Jeuland M, Cook J, Poulos C, Clemens J, Whittington D:. Group DCES. Cost-effectiveness of new-generation oral cholera vaccines: A multisite analysis. Value Health 2009; 12:899-908.
52. World Health Organisation. Cholera vaccines: WHO position paper. Wkly Epidemiol Rec 2010; 85:117-28.
53. Waldor MK, Hotez PJ, Clemens JD. A national cholera vaccine stockpile-a new humanitarian and diplomatic resource. New Engl J Med 2010; 363:2279-82.